<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04294771</url>
  </required_header>
  <id_info>
    <org_study_id>CIC1421-20-03</org_study_id>
    <nct_id>NCT04294771</nct_id>
  </id_info>
  <brief_title>JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors</brief_title>
  <acronym>JOCARDITE</acronym>
  <official_title>JOint Use of Database to Identify Risk Factors of CARDio-vascular Adverse Reactions Induced by Immune Checkpoint InhibiTors: VigiBase, Entrepot de Données de Santé (EDS) and Système National Des Données de Santé (SNDS) Databases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Hospitalier Pitie-Salpetriere</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immune checkpoint inhibitors (ICIs) might induce high grade immune-related adverse events
      (irAEs) involving the cardio-vascular system. This study investigates reports of
      cardio-vascular toxicity associated with treatment including anti-PD1, Anti-PDL-1, and Anti
      CTLA4 classes using the World Health Organization (WHO) database VigiBase, Assistance
      Publique Hopitaux de Paris Entrepot de Données de Santé (APHP.EDS) and French Système
      National Des Données de Santé (SNDS) Databases
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ICIs have dramatically improved clinical outcomes in multiple cancer types and are
      increasingly being tested in earlier disease settings and in combination. Thus, irAEs can
      occur and risk factors for such events have been scarcely described. Here, the investigators
      will use VigiBase (http://www.vigiaccess.org/), the World Health Organization (WHO) database
      of individual safety case reports, to identify risk factors for cases of cardiovascular
      adverse drug reaction following treatment with ICIs, the investigators will also use two
      french databases : APHP Entrepot de Données de Santé (EDS) and French Système National Des
      Données de Santé (SNDS) Databases
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identifying risk factors of cardio-vascular toxicity of ICIs.</measure>
    <time_frame>Case reported in the World Health Organization database (WHO) of individual safety case reports (VigiBase), APHP Entrepot de Données de Santé (EDS) and Système National Des Données de Santé (SNDS) Databases from inception to January 2021</time_frame>
    <description>Identifying risk factors of overreporting of cardiovascular adverse events in ICI treated patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Causality assessment of reported cardiovascular events</measure>
    <time_frame>Case reported in the World Health Organization database (WHO) of individual safety case reports (VigiBase), APHP Entrepot de Données de Santé (EDS) and Système National Des Données de Santé (SNDS) Databases from inception to January 2021</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the type of cardiotoxicity depending on the category of ICIs</measure>
    <time_frame>Case reported in the World Health Organization database (WHO) of individual safety case reports (VigiBase), APHP Entrepot de Données de Santé (EDS) and Système National Des Données de Santé (SNDS) Databases from inception to January 2021</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the duration of treatment when the toxicity happens (role of cumulative dose)</measure>
    <time_frame>Case reported in the World Health Organization database (WHO) of individual safety case reports (VigiBase), APHP Entrepot de Données de Santé (EDS) and Système National Des Données de Santé (SNDS) Databases from inception to January 2021</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the drug-drug interactions associated with adverse events</measure>
    <time_frame>Case reported in the World Health Organization database (WHO) of individual safety case reports (VigiBase), APHP Entrepot de Données de Santé (EDS) and Système National Des Données de Santé (SNDS) Databases from inception to January 2021</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the pathologies (cancer) for which the incriminated drugs have been prescribed</measure>
    <time_frame>Case reported in the World Health Organization database (WHO) of individual safety case reports (VigiBase), APHP Entrepot de Données de Santé (EDS) and Système National Des Données de Santé (SNDS) Databases from inception to January 2021</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of the population of patients having a cardio-vascular adverse event</measure>
    <time_frame>Case reported in the World Health Organization database (WHO) of individual safety case reports (VigiBase), APHP Entrepot de Données de Santé (EDS) and Système National Des Données de Santé (SNDS) Databases from inception to January 2021</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardio-vascular toxicity of ICIs.</measure>
    <time_frame>Case reported in the World Health Organization database (WHO) of individual safety case reports (VigiBase), APHP Entrepot de Données de Santé (EDS) and Système National Des Données de Santé (SNDS) Databases from inception to January 2021</time_frame>
    <description>Number of patients with cardiovascular adverse events with significant over-reporting ICIs</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500000</enrollment>
  <condition>Myocarditis</condition>
  <condition>Cardiomyopathies</condition>
  <condition>Heart Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Pericarditis</condition>
  <condition>Vasculitis</condition>
  <arm_group>
    <arm_group_label>Myocarditis and other cardiovascular toxicities ICI-related</arm_group_label>
    <description>Case reported in the World Health Organization (WHO)international pharmacovigilance database, or APHP Entrepot de Données de Santé (EDS) and French Système National Des Données de Santé (SNDS) Databases, with a chronology compatible with the drug toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non case</arm_group_label>
    <description>Non-case will be patients exposed to ICI without cardiovascular toxicities</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ICI</intervention_name>
    <description>Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the ATC following list (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC3)</description>
    <arm_group_label>Myocarditis and other cardiovascular toxicities ICI-related</arm_group_label>
    <arm_group_label>Non case</arm_group_label>
    <other_name>Immune checkpoint inhibitors</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with an ICI for a cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Case reported in the World Health Organization (WHO) database of individual safety
             case reports to 01/01/2021

          -  Case reported in the APHP Entrepot de Données de Santé (EDS) database of individual
             safety case reports to 01/01/2021

          -  Case reported in the Système National Des Données de Santé (SNDS) Database of
             individual safety case reports to 01/01/2021

          -  Adverse event reported were including the MedDRA terms: Cardiac and vascular
             investigations (excl enzyme tests) (HLGT), Vascular disorders (SOC), Skeletal and
             cardiac muscle analyses (HLT), Sudden death (PT), Sudden cardiac death (PT), Cardiac
             disorders (SOC), Cardiac arrhythmias (HLGT), Cardiac disorder signs and symptoms
             (HLGT), Cardiac neoplasms (HLGT), Cardiac valve disorders (HLGT), Congenital cardiac
             disorders (HLGT), Coronary artery disorders (HLGT), Endocardial disorders (HLGT),
             Heart failures (HLGT), Myocardial disorders (HLGT), Pericardial disorders (HLGT)

          -  Patients treated with ICIs included in the ATC: Ipilimumab (L01XC11), Nivolumab
             (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31),
             Atezolizumab (L01XC32), Cemiplimab (L01XC33)

        Exclusion Criteria:

          -  Chronology not compatible between the drug and the toxicity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM.</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018 Mar 10;391(10124):933. doi: 10.1016/S0140-6736(18)30533-6.</citation>
    <PMID>29536852</PMID>
  </reference>
  <reference>
    <citation>Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018 Dec;19(12):1579-1589. doi: 10.1016/S1470-2045(18)30608-9. Epub 2018 Nov 12.</citation>
    <PMID>30442497</PMID>
  </reference>
  <reference>
    <citation>Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, Kerneis M. Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis. N Engl J Med. 2019 Jun 13;380(24):2377-2379. doi: 10.1056/NEJMc1901677.</citation>
    <PMID>31189043</PMID>
  </reference>
  <reference>
    <citation>Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, Stewart GC, Choueiri TK, Di Carli M, Allenbach Y, Kumbhani DJ, Heinzerling L, Amiri-Kordestani L, Lyon AR, Thavendiranathan P, Padera R, Lichtman A, Liu PP, Johnson DB, Moslehi J. Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology. Circulation. 2019 Jul 2;140(2):80-91. Review.</citation>
    <PMID>31390169</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2020</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Groupe Hospitalier Pitie-Salpetriere</investigator_affiliation>
    <investigator_full_name>Joe Elie Salem</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Drug-induced cardiotoxicity</keyword>
  <keyword>Immune Checkpoint Inhibitors</keyword>
  <keyword>Anti-PD-1</keyword>
  <keyword>Anti-PD-L1</keyword>
  <keyword>Anti CTLA-4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Myocarditis</mesh_term>
    <mesh_term>Pericarditis</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

